-
2023-504135-40-00
Classical Homocystinuria
-
2023-505200-33-00
Multiple myeloma
-
2023-508062-15-00
Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 an
-
2023-509392-17-00
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-511114-20-00
Craniopharyngioma
-
2024-511807-41-01
Hemophagocytic lymphohistiocytosis (HLH)
-
2024-512763-32-00
Patients diagnosed at the study sites with rifampicinre
-
2024-513445-37-00
previously untreated RT, irrespective of risk factors a
-
2024-513528-41-02
Sickle cell anaemia
-
2024-513676-18-00
Transthyretin Amyloidosis
-
2024-513889-19-00
Multiple Myeloma
-
2024-514244-81-00
Uncomplicated candidemia
-
2024-515287-31-00
Giant Cell Arteritis
-
2024-515598-82-00
Voltage-gated sodium channel type II alpha subunit (SCN
-
2024-516018-39-00
Erythema multiforme (EM) in its severe form managed at
-
2024-516335-27-00
anti-MAG neuropathy
-
2024-516503-17-01
Diagnosed and histopathologically confirmed diffuse or
-
2024-516721-31-00
Non-24 Hour Sleep-Wake Disorder
-
2024-517133-40-00
newly diagnosed, non-metastatic, SHH-activated, TP53-wt
-
2024-517295-37-00
low and intermediate risk neuroblastoma
-
2024-517485-42-00
Non-psychotic therapy resistant unipolar depression
-
2024-517595-38-00
Thrombotic episodes in superficial venous malformations
-
2024-517688-21-00
Recurrent Pericarditis
-
2024-518349-85-01
small bowel adenocarcinoma